Increased fibrin formation in blood in women above the age of 30 who are both oral contraceptive users and smokers

Fibrinolysis

Volumn 10, Issue 1, 1996, Pages 9-13

  Jespersen, J ^a,b   Gram, J ^a,b  

^a ESBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; FIBRIN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOSIS;

EID: 0029918525     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(05)80070-0     Document Type: Article

References (26)

1. Royal College of General Practitioners. Further analyses of mortality in oral contraceptive users. Lancet 1981 ; 1: 541-6.
2. Vessey M P, Villard-Mackintoch L, McPherson K, Yeates D. Mortality in oral contraceptives users: 20 years follow-up of women in a large cohort study. BMJ 1989; 299: 1487-91.
3. Inman W H W, Vessey M P. Investigation of deaths from pulmonary, coronary and cerebral thrombosis and embolism in women of child-bearing age. BMJ 1968; 2: 193-9.
4. Mann J I, Inman W H W. Oral contraceptives and death from myocardial infarction. BMJ 1975; 2: 245-8.
5. Mann J I, Inman W H W, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. BMJ 1975; 2: 445-7.
6. Adam S A, Thorogood M, Mann J I. Oral contraception and myocardial infarction revisited: the effects of new preparations and prescribing patterns. Br J Obstet Gynaecol 1981; 88: 838-45.
7. Gaspard U, Jespersen J, Kluft C, Mattson L Å, Samsioe G, Skouby S O. Consensus development meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990; 162: 1335-7.
8. The Society for the Advancement of Contraception, The International Committee for Research in Reproduction. Consensus Statements. Adv Contracept 1991; 7 (Suppl 3): 3-5.
9. Thorogood M, Vessey M P. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol 1990; 163: 274-81.
10. Kay C R. The Royal College of General Practitioners' Oral Contraception Study: some recent observations. Clin Obstet Gynaecol 1984; 11: 759-86.
11. Croft P, Hannaford P C. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' Oral Contraceptive Study. BMJ 1989; 298: 165-8.
12. Verheijen J H. Mullaart E, Chang G T G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay of extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-9.
13. Meade R W, Haines A P, North W R S, Chakrabarti R, Howarth D J, Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet 1977; 2: 948-51.
14. Gevers Leuven J A, Drijkoningen G J A, Alers J, Havekes L, Dersjant-Roorda M. The effect of low dose oral contraceptives on lipoprotein lipid and apolipoprotein levels in smoking and non-smoking women. J Drug Therap Res 1988; 13: 355-9.
15. Gevers Leuven JA, Dersjant-Roorda MC, Helmerhorst FM, de Boer R, Neymeyer-LeLoux A, Havekes L. Estrogenic effect of gestodene - or desogestrel - containing oral contraceptives on oral lipoprotein metabolism. Am J Obstet Gynecol 1990; 163: 358-62.
16. Samsioe G, Mattson L-Å. Some aspects of the relationship between oral contraceptives, lipid abnormalities, and cardiovascular disease. Am J Obstet Gynecol 1990; 163: 354-8.
17. Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781-806.
18. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-9.
19. Hoylaerts M, Rijken D C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-9.
20. Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull 1988; 35: 1-33.
21. Bonnar J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv Contracept 1991; 7(Suppl 3): 285-91.
22. Winkler U H, Koslowski S, Oberhoff C, Schindler E M, Schindler A E. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv Contracept 1991; 7 (Suppl 3): 273-84.
23. Robinson G E, Burren T, Mackie I J et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ 1991; 302: 269-71.
24. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994; 128: 7-11.
25. Gram J, Munkvad S, Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in oestrogen. Am J Obstet Gynecol 1990; 163: 438-42.
26. Jespersen J, Petersen K R, Skouby S O. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163: 396-403.